Re: [114attendees] [114all] Consultation on COVID management for IETF 115 London

ProSapien Sam Smith <sam@prosapien.com> Fri, 12 August 2022 18:55 UTC

Return-Path: <sam@prosapien.com>
X-Original-To: 114attendees@ietfa.amsl.com
Delivered-To: 114attendees@ietfa.amsl.com
Received: from localhost (localhost [127.0.0.1]) by ietfa.amsl.com (Postfix) with ESMTP id 4331BC14F72F for <114attendees@ietfa.amsl.com>; Fri, 12 Aug 2022 11:55:04 -0700 (PDT)
X-Virus-Scanned: amavisd-new at amsl.com
X-Spam-Flag: NO
X-Spam-Score: 0.33
X-Spam-Level:
X-Spam-Status: No, score=0.33 tagged_above=-999 required=5 tests=[BAYES_00=-1.9, DKIM_INVALID=0.1, DKIM_SIGNED=0.1, HTML_MESSAGE=0.001, LONGWORDS=2.035, RCVD_IN_DNSWL_BLOCKED=0.001, SPF_HELO_NONE=0.001, SPF_PASS=-0.001, T_SCC_BODY_TEXT_LINE=-0.01, URIBL_BLOCKED=0.001, URIBL_DBL_BLOCKED_OPENDNS=0.001, URIBL_ZEN_BLOCKED_OPENDNS=0.001] autolearn=no autolearn_force=no
Authentication-Results: ietfa.amsl.com (amavisd-new); dkim=neutral reason="invalid (public key: OpenSSL error: bad base64 decode)" header.d=prosapien.com
Received: from mail.ietf.org ([50.223.129.194]) by localhost (ietfa.amsl.com [127.0.0.1]) (amavisd-new, port 10024) with ESMTP id lu8uU_2zERBW for <114attendees@ietfa.amsl.com>; Fri, 12 Aug 2022 11:55:00 -0700 (PDT)
Received: from mail-il1-x134.google.com (mail-il1-x134.google.com [IPv6:2607:f8b0:4864:20::134]) (using TLSv1.3 with cipher TLS_AES_128_GCM_SHA256 (128/128 bits) key-exchange X25519 server-signature RSA-PSS (2048 bits) server-digest SHA256) (No client certificate requested) by ietfa.amsl.com (Postfix) with ESMTPS id F2530C14CF0C for <114attendees@ietf.org>; Fri, 12 Aug 2022 11:54:59 -0700 (PDT)
Received: by mail-il1-x134.google.com with SMTP id j20so925484ila.6 for <114attendees@ietf.org>; Fri, 12 Aug 2022 11:54:59 -0700 (PDT)
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=prosapien.com; s=google; h=references:to:in-reply-to:subject:date:mime-version:message-id:from :from:to:cc; bh=ZlSm789lGlUstQ/WggzxlfehZFhBhbJDWo1X/1NC1mI=; b=Te3Vgx7aFaE9Z6D4MF+wYUuKqx08DDz7lbhYGal9Vsaje/q5zgdBKF+oUlDgrO96cQ rSb9wCYi7GNTS+iyGqdppp4H81flqrRlbPCkHODoDWetYp3ek7koGkFPPI+BTMj8hiQw /6EIn2ebRTUbi/Uobh6bUhTChCv3RMIjerLgFQYix+cEA5aEEuSfVIXyRiXDRHWqAWny /9771WAOTQUDd+JgduBcdHb6HTJb7wxrurzvYvyuadjoEnjiTxf2P8XnndrwC2kaHoPJ eoG/1ZgkyiAOpDg2sRNHrCjTYFkG8lF/RFGwn8LQ5gAITks0NQ9sgFQZit/PxIoVt6Nv QZDw==
X-Google-DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=1e100.net; s=20210112; h=references:to:in-reply-to:subject:date:mime-version:message-id:from :x-gm-message-state:from:to:cc; bh=ZlSm789lGlUstQ/WggzxlfehZFhBhbJDWo1X/1NC1mI=; b=y/3uHBhp4KJykxqWO1CaixbWbyJ3wU/pvwmPdRR4vUgazHGuoqVdcLEG/JeTHTVI1Z SwSmxhCedhQ8qd6HVZ+RoGEnhuINe3LJQswo+iYzkFkt357w5M/OfWR/A+A4baAsPk3p RlvCT7WkKbfO4R+tZnOx/36sNE4/Kq4aMnDc8NpX5OSl4cWr4IOknGOmQYL1hRFsu22W rjbTGMj/ZKT28ifpcUuUvS9Q0nyoAjWTgDMMJJA5rd8loi8Lq1iFmwWmdc3cK6uUELTI wsZj1hFItiz99uVr6hQAG4pDJy7Ni3L9lONqXrEeCPufI/4Zm8seBQDCz9ww1imUZWSA y0cg==
X-Gm-Message-State: ACgBeo1IFwWQYior/dbqdnkhLxJeyTJKskTD126s8jyx8liHx+kTk/nb DLxAb3RdVzLeEEsK4fpiBppjjXhM3gnWug==
X-Google-Smtp-Source: AA6agR56NMfwBayWZ4xL3MxWe3502gCifSFikO2+IdAFSu6idhrVTAtuG9QqS8qm2Ig6BD1AI86MBg==
X-Received: by 2002:a05:6e02:661:b0:2e2:be22:67f0 with SMTP id l1-20020a056e02066100b002e2be2267f0mr2481713ilt.91.1660330497598; Fri, 12 Aug 2022 11:54:57 -0700 (PDT)
Received: from smtpclient.apple ([166.70.16.84]) by smtp.gmail.com with ESMTPSA id j9-20020a0566022cc900b0067be568081fsm1248703iow.43.2022.08.12.11.54.57 (version=TLS1_2 cipher=ECDHE-ECDSA-AES128-GCM-SHA256 bits=128/128); Fri, 12 Aug 2022 11:54:57 -0700 (PDT)
From: ProSapien Sam Smith <sam@prosapien.com>
Message-Id: <3073761B-3B29-4FC1-9AB6-B71AA9E6CF38@prosapien.com>
Content-Type: multipart/alternative; boundary="Apple-Mail=_DC003CCE-225B-4638-95E4-7E7BA700BB74"
Mime-Version: 1.0 (Mac OS X Mail 16.0 \(3696.120.41.1.1\))
Date: Fri, 12 Aug 2022 12:54:56 -0600
In-Reply-To: <mailman.6927.1660329885.12854.114all@ietf.org>
To: 114attendees@ietf.org
References: <mailman.6927.1660329885.12854.114all@ietf.org>
X-Mailer: Apple Mail (2.3696.120.41.1.1)
Archived-At: <https://mailarchive.ietf.org/arch/msg/114attendees/HMSaiyhpr2z28QWMIHjAX3Splzw>
Subject: Re: [114attendees] [114all] Consultation on COVID management for IETF 115 London
X-BeenThere: 114attendees@ietf.org
X-Mailman-Version: 2.1.39
Precedence: list
List-Id: Mailing list for IETF 114 attendees <114attendees.ietf.org>
List-Unsubscribe: <https://www.ietf.org/mailman/options/114attendees>, <mailto:114attendees-request@ietf.org?subject=unsubscribe>
List-Archive: <https://mailarchive.ietf.org/arch/browse/114attendees/>
List-Post: <mailto:114attendees@ietf.org>
List-Help: <mailto:114attendees-request@ietf.org?subject=help>
List-Subscribe: <https://www.ietf.org/mailman/listinfo/114attendees>, <mailto:114attendees-request@ietf.org?subject=subscribe>
X-List-Received-Date: Fri, 12 Aug 2022 18:55:04 -0000


> On 12 Aug 2022, at 12:44 , 114all-owner@ietf.org wrote:
> 
> Only authorized senders may post to this list. Please use
> 114attendees@ietf.org for discussion.
> 
> 
> From: ProSapien Sam Smith <sam@prosapien.com>
> Subject: Re: [114all] Consultation on COVID management for IETF 115 London
> Date: 12 August 2022 at 12:44:37 MDT
> To: admin-discuss@ietf.org
> Cc: IETF Announcement List <ietf-announce@ietf.org>, 114all@ietf.org, 115all@ietf.org
> 
> 
> Given this recent report in Science magazine, 
> 
> https://www.science.org/doi/10.1126/science.abq1841 <https://www.science.org/doi/10.1126/science.abq1841>
> 
> it seems that the proposed policy does not reflect the underlying science about the behavior of the dominant variants of Covid nor the efficacy of that policy. It's not clear what the policy is trying to accomplish.
> 
> It's one thing to attempt to prevent transmission in general.  It's another to attempt to minimize severe symptoms of any given individual, yet another to attempt to prevent infection or reinfection of any given individual, and finally, another to merely assuage the fears of the attendees.
> 
> For example, according to the article above, immune imprinting resulting from prior infection on vaccinated, and/or boosted individuals can increase reinfection rates of escape mutant variants such as omicron.
> 
> Likewise, this article shows that primary infection alone without vaccination provides highly effective protection against severe symptoms of all known variants. 
> 
> https://www.medrxiv.org/content/10.1101/2022.07.06.22277306v1.full-text <https://www.medrxiv.org/content/10.1101/2022.07.06.22277306v1.full-text>
> 
> "Effectiveness of primary infection against severe, critical, or fatal COVID-19 reinfection was 97.3% (95% CI: 94.9- 98.6%), irrespective of the variant of primary infection or reinfection, and with no evidence for waning. Similar results were found in sub-group analyses for those ≥50 years of age."
> 
> An article in Nature https://www.nature.com/articles/d41586-022-01914-6 <https://www.nature.com/articles/d41586-022-01914-6> about the Quatar study above concludes:
> 
> "Regardless of the extrapolations, the data indicate that naturally acquired immunity is hardy — something that is not always championed."
> 
> The science of Covid  and hence science-based Covid policy is much more complex than the policy recommendations here exhibit.
> 
> It is difficult to comment for or against the policy without clear policy goals as per my original question.
> 
> 
> 
> 
>> On 12 Aug 2022, at 07:20 , IETF Executive Director <exec-director@ietf.org <mailto:exec-director@ietf.org>> wrote:
>> 
>> The IETF Administration LLC and IESG are considering what COVID management to implement for IETF 115 London and now seek community feedback on our proposed way forward.
>> 
>> First, some data:
>> - For IETF 113 Vienna we had 9 reported cases from 314 onsite participants (2.9%)
>> - For IETF 114 Philadelphia we had 16 reported cases and 2 people who were ill but tested negative, from 622 onsite participants (2.6% at 16, 2.9% at 18)
>> 
>> 
>> We propose to continue with COVID management restrictions for IETF 115 London and to base these on those in place for IETF 114, with some notable tightening as follows:
>> 
>> 1.  Vaccines
>> We propose to continue to require vaccines, continue with a self-declaration at registration and no other form of checking, and to amend the language to include boosters as follows:
>> 	"I confirm that I am fully vaccinated and boosted with a vaccine from the WHO Emergency Use List."
>> 
>> We propose to continue with the following guidance on what that means:
>> 	"As the definition of fully vaccinated and boosted varies between countries, please answer this based on the guidance of your national health protection agency or equivalent body."
>> 
>> 
>> 2.  Masks
>> We propose the following set of rules regarding masks:
>> 
>> - Masks must be worn in both meeting rooms and common areas set aside for our exclusive use.  This is a tightening from IETF 114 where masks could be removed in common areas.
>> 
>> - Masks can be removed for eating and drinking but that should not be an excuse to leave them off for long periods.  Previously no guidance was provided on leaving a mask off for a long period.
>> 
>> - Active speakers in sessions who are at the front of the room presenting or speaking in the mic queue, can remove their mask while speaking if they need to remove the mask to be understood.  This restriction to being understood is a tightening of the rule from IETF 114.
>> 
>> - Exemption certificates will not be honoured.  This is the same as for IETF 114.
>> 
>> - Masks must be FFP2 or equivalent and we will continue to make those freely available.  This is the same as for IETF 114, however at that meeting there were multiple examples of people wearing surgical or even less effective masks and little action was taken.  We propose for IETF 115 that a group of senior LLC/Secretariat staff will manage this by offering those wearing such masks, FFP2 masks as replacements.
>> 
>> - Finally, we note that we are in active negotiations with the venue for their staff to wear masks when in our exclusive use areas.
>> 
>> 
>> 3.  Testing
>> We propose to continue with voluntary testing and to make rapid antigen tests freely available to onsite participants.
>> 
>> 
>> Please provide feedback on this proposal either to the public list admin-discuss@ietf, or directly to me at exec-director@ietf.org <mailto:exec-director@ietf.org>, before 29th August 2022.
>> 
>> 
>> -- 
>> Jay Daley
>> IETF Executive Director
>> exec-director@ietf.org <mailto:exec-director@ietf.org>
>> 
>> -- 
>> 114all mailing list
>> 114all@ietf.org
>> https://www.ietf.org/mailman/listinfo/114all
> 
> 
>